[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
28-Apr-2010

[ | E-mail ] Share Share

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-319-22165
BioMed Central
@biomedcentral

Curcumin nanoparticles 'open up' resistant cancers

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemotherapy and radiotherapy. Researchers writing in BioMed Central's open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

Subhash Chauhan, PhD, and Meena Jaggi, PhD, led a team of researchers from Sanford Research and the University of South Dakota, USA, who carried out the in vitro study. They said, "One strategy to improve the effectiveness and limit the toxicity of cancer therapy is to induce chemo/radio-sensitization in cancer cells using natural dietary phytochemicals like curcumin. However, curcumin is poorly absorbed by the body, which limits its effectiveness. We have developed a nanoparticle formulation, Nano-CUR, to provide increased bioavailability as well as targeted delivery of curcumin into tumors".

The researchers tested the effects of their curcumin formulation on therapy-resistant ovarian cancer cells. They were able to show, for the first time, that the pre-treatment lowers the dose of cisplatin and radiation treatment needed to suppress the growth of the cancer cells. According to Chauhan, "Nanoparticle mediated curcumin delivery will further improve the sensitization and therapeutic capabilities. This study demonstrates a novel pre-treatment strategy that could be implemented in pre-clinical animal models and in future clinical trials".

###

Notes to Editors

1. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth
Murali M Yallapu, Diane M Maher, Vasudha Sundram, Maria C Bell, Meena Jaggi and Subhash C Chauhan
Journal of Ovarian Research (in press)

During embargo, article available here: http://www.ovarianresearch.com/imedia/5213824743515181_article.pdf?random=247872

After the embargo, article available at the journal website: http://www.ovarianresearch.com/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication.

2. Journal of Ovarian Research aims to provide a forum for high-quality basic and clinical research on ovarian functions, abnormalities, as well as prevention and treatment of diseases afflicting the organ.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.